이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Kiromic BioPharma 관리

관리 기준 확인 0/4

Kiromic BioPharma's CEO는 Pietro Bersani, Jan2022 에 임명되었습니다 의 임기는 1.42 년입니다. 총 연간 보상은 $ 697.49K, 71.2% 로 구성됩니다. 71.2% 급여 및 28.8% 보너스(회사 주식 및 옵션 포함). 는 € 60.70K 가치에 해당하는 회사 주식의 2.19% 직접 소유합니다. 60.70K. 경영진과 이사회의 평균 재임 기간은 각각 0.9 년과 2.7 년입니다.

주요 정보

Pietro Bersani

최고 경영자

US$697.5k

총 보상

CEO 급여 비율	71.2%
CEO 임기	1.4yrs
CEO 소유권	2.2%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	2.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Pietro Bersani 의 보수는 Kiromic BioPharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2023	n/a	n/a	-US$33m
Dec 31 2022	US$697k	US$497k	-US$35m
Sep 30 2022	n/a	n/a	-US$39m
Jun 30 2022	n/a	n/a	-US$33m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	US$336k	US$168k	-US$26m
Sep 30 2021	n/a	n/a	-US$19m
Jun 30 2021	n/a	n/a	-US$15m
Mar 31 2021	n/a	n/a	-US$22m
Dec 31 2020	US$63k	n/a	-US$20m

보상 대 시장: Pietro 의 총 보상 ($USD 697.49K )은 German 시장( $USD 434.78K ).

보상과 수익: 회사가 수익성이 없는 동안 Pietro 의 보상이 증가했습니다.

CEO

Pietro Bersani (55 yo)

1.4yrs

테뉴어

US$697,486

보상

Mr. Pietro Bersani, CPA, J.D., serves as Chief Executive Officer at Kiromic BioPharma, Inc. since May 10, 2022 and serves as Director since January 27, 2022. He serves as Principal Financial Officer at Kir...

리더십 팀

이름	위치	테뉴어	보상	소유권
Pietro Bersani	CEO, Principal Financial Officer & Director	1.4yrs	US$697.49k	2.19% $ 60.7k
Jason Morris	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Leonardo Mirandola	CSO & Interim COO	less than a year	데이터 없음	0.013% $ 373.5
Scott Dahlbeck	Chief of Staff	3.7yrs	US$442.12k	0% $ 0
Timothy Simkiss	Controller	less than a year	데이터 없음	데이터 없음

0.9yrs

평균 재임 기간

경험이 풍부한 관리: 5JU0 의 관리팀은 경험 (평균 재직 기간 0.9 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Pietro Bersani	CEO, Principal Financial Officer & Director	3yrs	US$697.49k	2.19% $ 60.7k
Michael Nagel	Independent Chairperson of the Board	2.7yrs	US$214.20k	0.64% $ 17.8k
Ruggero De Maria	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Americo Cicchetti	Independent Director	3.3yrs	US$187.96k	0.64% $ 17.8k
Amorette Barber	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Martin D'Souza	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Sandeep Dhanda	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Luca Gattinoni	Member of Scientific Advisory Board	2.4yrs	데이터 없음	데이터 없음
Franco Locatelli	Member of Scientific Advisory Board	1.8yrs	데이터 없음	데이터 없음

2.7yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 이사회: 5JU0 의 이사회는 경험(평균 재직 기간 2.7 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Kiromic BioPharma 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Kiromic BioPharma, Inc., Annual General Meeting, Jun 26, 2024

Kiromic Biopharma, Inc. Announces Board Appointments

Kiromic BioPharma, Inc., Annual General Meeting, Jul 25, 2023

Kiromic Biopharma, Inc Appoints Brian Hungerford as Interim Chief Financial Officer

Kiromic BioPharma, Inc. Announces the Resignation of Dan Clark as Chief Financial Officer

Kiromic Biopharma, Inc. Announces Resignation of Karen Reeves as Director

Recent updates

Kiromic BioPharma, Inc. Provides Updates on Its Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc., Annual General Meeting, Jun 26, 2024

Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients

Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Announces Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months

Kiromic Biopharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer

Kiromic Biopharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial

Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer

Nasdaq to Delist the Securities of Kiromic BioPharma

Kiromic Biopharma, Inc. Announces Deltacel™? Phase 1 Clinical Trial Enters Patient Recruitment Phase At Beverly Hills Cancer Center

Kiromic BioPharma, Inc.(OTCPK:KRBP) dropped from NASDAQ Composite Index

Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14, 2023, Suspended from Trading on Nasdaq Capital Market

Kiromic Biopharma, Inc. Announces Board Appointments

Kiromic BioPharma, Inc. announced that it has received $2.4 million in funding

Kiromic BioPharma, Inc., Annual General Meeting, Jul 25, 2023

Kiromic Biopharma, Inc Appoints Brian Hungerford as Interim Chief Financial Officer

Kiromic BioPharma, Inc. Announces the Resignation of Dan Clark as Chief Financial Officer

Kiromic Biopharma, Inc. Announces Resignation of Karen Reeves as Director

Kiromic BioPharma Receives Non-Compliance Notice from Nasdaq

Frank Tirelli Resigns His Position as Director and Member of the Audit Committee, and the Nominating and Corporate Governance Committee of Kiromic Biopharma, Inc

High number of new and inexperienced directors

Kiromic BioPharma, Inc. announced that it has received $2 million in funding

Kiromic Biopharma Announces FDA Feedback from Type B Pre-Ind Meeting Confirms Deltacel Development Strategy

Gainey Mckenna & Egleston Files the First Class Action Lawsuit Against Kiromic Biopharma, Inc

Nasdaq Grants Extension to Kiromic BioPharma to Regain Compliance

The Klein Law Firm Announces Class Action Complaint Against Kiromic Biopharma, Inc

Gainey McKenna & Egleston Files Class Action Lawsuit Against Kiromic BioPharma, Inc

Kiromic BioPharma, Inc. Appoints Leonardo Mirandola as Chief Scientific Officer

High number of new and inexperienced directors

Kiromic BioPharma, Inc. Appoints Pietro Bersani to the Role of Chief Executive Officer, Effective May 10, 2022

Kiromic BioPharma, Inc. Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022

Kiromic BioPharma, Inc., Annual General Meeting, Jun 22, 2022

Kiromic BioPharma, Inc. announced delayed annual 10-K filing

Kiromic BioPharma, Inc. Announces Board Appointments

High number of new and inexperienced directors

Kiromic BioPharma Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

High number of new and inexperienced directors

Kiromic BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $40 million.

Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy

Kiromic Biopharma, Inc. Announces Identification of Novel Targets for Allogeneic Car Gamma Delta T-Cell Therapy in Solid Tumors Utilizing Kiromic’s Proprietary Artificial Intelligence Engine

Kiromic BioPharma, Inc. Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter: First-In-Human, Off-The-Shelf Chimeric PD1 Switch Receptor - Gamma Delta T-cell Therapy

Kiromic Biopharma, Inc. to Resubmit Two Expanded INDs to the FDA for its Allogenic, Off-the-Shelf Gamma-Delta T cell Therapies for Multiple Solid Tumors

Kiromic Biopharma, Inc. Enters into A Strategic Alliance Agreement with Leon Office (H.K.) Ltd

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령